<DOC>
	<DOCNO>NCT01019616</DOCNO>
	<brief_summary>The purpose phase Ⅲ , multi-center , prospective , open-label , randomize , control study determine whether alternative non-cross-resistant adjuvant chemotherapy increase distant disease free survival ( DDFS ) operable patient non-response primary chemotherapy .</brief_summary>
	<brief_title>Alternative Non-cross-resistant Adjuvant Chemotherapy Operable Breast Cancer Non-response Primary Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Female patient , age ≦65 year Biopsy proven lymph node positive , estrogen receptor positive primary breast cancer Must complete 4cycle neoadjuvant chemotherapy standard regimen ( contain anthracycline paclitaxel ) Must undergone surgery remove primary tumor either mastectomy enlarge local excision Postoperative residual positive lymph node G1/G2/G3 Miller &amp; Payne Grading System Adequate recovery recent surgery No history malignancies No currently uncontrolled diseased active infection Not pregnant breast feeding , appropriate birth control childbearing potential Adequate cardiovascular function reserve myocardial infarction within past six month Adequate hematologic function : 1 . Absolute neutrophil count ( ANC ) ≥1500/mm3 2 . Platelets ≥100,000/ mm3 3 . Hemoglobin ≥10 g/dL Adequate hepatic renal function : 1 . Serum bilirubin ≤1.5×UNL 2 . Alkaline phosphatase alanine aminotransferase ( ALT ) ≤2.5 x ULN . ( ≤5 x ULN acceptable set hepatic metastasis ) 3 . BUN 1.7 8.3 mmol/L 4 . Cr 40 110 umol/L Knowledge investigational nature study Ability give inform consent Ability willingness comply study procedure . Known suspect distant metastasis Concurrent malignancy history malignancy Uncontrolled disease ( e.g. , heart failure , myocardial infarction within 6 month , arrhythmia , unstable diabetes , hypercalcemia ) active infection Geographical , social , psychological problem would compromise study compliance Known suspect hypersensitivity anthracycline paclitaxel</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>